Loading
A Stockholm prostate cancer researcher who led the STHLM3 study, which built a blood-and-genetics risk score for deciding which men need a prostate biopsy.
Henrik Grönberg was first author of the 2015 Lancet Oncology report of STHLM3, a population-based study in Stockholm men aged 50 to 69 that combined PSA, other plasma proteins, 232 genetic markers and clinical details into a single risk score; at the sensitivity of a PSA cutoff of 3 ng/mL it could have reduced biopsies by 32 per cent. Grönberg was a co-author of the STHLM3-MRI screening trial in the New England Journal of Medicine in 2021 and of its two-year follow-up in 2026, and of ALASCCA, the 2025 trial of low-dose aspirin after surgery for colorectal cancer with PI3K pathway alterations. Grönberg's 2026 papers give the affiliations as the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and the Department of Surgery at Capio S:t Göran's Hospital, and include the protocol of ProBio-mHSPC, a ctDNA-guided platform trial in metastatic hormone-sensitive prostate cancer.
| Title | Journal | Year |
|---|---|---|
| Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study | Lancet Oncology | 2015 |
| MRI-targeted or standard biopsy in prostate cancer screening | New England Journal of Medicine | 2021 |
| Stockholm3-magnetic resonance imaging population-based prostate cancer screening study: two-year follow-up | Annals of Internal Medicine | 2026 |
This is the paper Europe PMC returns for registry id NCT02647099 with the most citations, so it is the natural first reading for anyone following the ALASCCA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Overdiagnosis, finding cancers that would never have caused harm, is the main reason Sweden's health authority advises against PSA screening. This trial showed that putting an MRI before the biopsy keeps the detection of cancers that matter while cutting the harmless ones by about two thirds. Sweden's regions have since begun organised prostate cancer testing, which the regional cancer centres describe as making PSA testing more equal and structured and helping to evaluate complementary tests; Socialstyrelsen still distinguishes it from screening.
It showed in a general population, not a referred clinic population, that a multi-marker risk score could spare many men a biopsy without missing more of the cancers that matter. The same group then tested the score inside the STHLM3-MRI screening trial.
Shares Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer, Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study, STHLM3-MRI (Stockholm3 and MRI-targeted biopsy in prostate cancer screening), MRI-targeted or standard biopsy in prostate cancer screening (STHLM3-MRI).
Shares Overdiagnosis, PSA (prostate-specific antigen), Prostate cancer.
Shares Overdiagnosis, PSA (prostate-specific antigen), Prostate cancer.
Shares STHLM3-MRI (Stockholm3 and MRI-targeted biopsy in prostate cancer screening), MRI-targeted or standard biopsy in prostate cancer screening (STHLM3-MRI), Overdiagnosis, PSA (prostate-specific antigen).
Shares Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study, Overdiagnosis, PSA (prostate-specific antigen), Prostate cancer.
Shares Overdiagnosis, PSA (prostate-specific antigen), Prostate cancer.
Shares STHLM3-MRI (Stockholm3 and MRI-targeted biopsy in prostate cancer screening), MRI-targeted or standard biopsy in prostate cancer screening (STHLM3-MRI), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/